Pompe Disease (Late-onset)NCT05272969
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
An observational study of Pompe Disease (Late-onset) and Inclusion Body Myositis, run by LMU Klinikum at 1 site in Germany.
Trial summary
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pompe Disease (Late-onset), Inclusion Body Myositis, Spinal Muscular Atrophy Type 3
- What is being tested?
- Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire) and German Pain Inventory (Questionnaire)
- Type of treatment
- Injection or infusion
- How many people
- 95 participants
- Where
- 1 siteGermany
- Study dates
- 31 Mar 2022to 3 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: After screening of 120 patients, approximately 50 patients with late-onset Pompe disease, 15 patients with IBM, 15 patients with FSHD and 15 patients with SMA3, who meet all eligibility criteria, will be enrolled in the study. All patients must be ≥ 18 years of age.
Inclusion Criteria: A patient must meet the following criteria to be eligible for this study:
- The patient is willing and able to provide signed informed consent.
- The patient is able and willing to perform study-related assessments.
- A) The patient is ≥18 years of age with acid α-glucosidase [GAA] enzyme deficiency, confirmed by GAA gene mutation analysis, or B) The patient has a histologically confirmed diagnosis of inclusion body myositis (IBM), or a genetically confirmed spinal muscular atrophy type 3 (SMA3) or a genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).
Exclusion Criteria: A patient who meets any of the following criteria will be excluded from this study.
- The patient is participating in another clinical study or using an investigational treatment.
- The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
- The patient has currently a severe depression, assessed by the Beck depression inventory fast screen (BDI-FS) with a score ≥ 4
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen
Munich, Bavaria, 80336
Stephan Wenninger, MD, +4989440057470, stephan.wenninger@med.uni-muenchen.de
About this study
Official title: Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD)
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). The secondary objectives are to evaluate whether muscle pain is associated with muscle function, to assess whether muscle pain is associated with alterations of muscle tissue, and whether vitamin D metabolism and polymorphisms of ACE and ACTN3 genes may contribute to an increased level of perceived musculoskeletal pain. In a second step, exome sequencing of genes associated with musculoskeletal pain will be analyzed. Results of LOPD patients will be compared to patients with neuromuscular disorders with a similar distribution of muscle weakness and/or musculoskeletal pain.
Read the detailed description
In this nationwide, explorative, cross-sectional study in Germany, approx. 50 patients with genetically confirmed late-onset Pompe disease (LOPD) will be included into the study. In addition, 15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group. The duration of patient recruitment will be around 18 months. The primary aim is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). The secondary objectives are to evaluate whether muscle pain is associated with muscle function, measured by quantitative muscle testing and pressure pain threshold (PPT), to assess whether muscle pain is associated with alterations of muscle tissue, measured by muscle ultrasound and whether vitamin D metabolism and polymorphisms of ACE and ACTN3 genes may contribute to an increased level of perceived musculoskeletal pain. In a second step, exome sequencing of genes associated with musculoskeletal pain will be analyzed. Results of LOPD patients will be compared to patients with neuromuscular disorders with a similar distribution of muscle weakness and/or musculoskeletal pain.
After screening of 120 patients, approximately 50 patients with late-onset Pompe disease, 15 patients with IBM, 15 patients with FSHD and 15 patients with SMA3, who meet all eligibility criteria, will be enrolled in the study. All patients will be required to attend once at a study site to perform all study-related procedures. The study procedures will take approx. 3 hours.
Demographic and disease-related data (age, gender, weight, height, diagnosis, a historical genetic test results and/or muscle biopsy results, age at onset of symptoms, age at diagnosis, severity and distribution of muscle weakness, prior and concomitant medication, medical history, ventilation status) will be obtained. Patients will fill out validated disease-related and quality-of-life questionnaires: Brief Pain Inventory, Rotterdam Handicap Scale, Fatigue Severity Scale, R-PAct, and German Pain Questionnaire. Patients will be asked to sketch regions of perceived musculoskeletal pain on a body figure, which is provided on a tablet or a paper version. The paper version will be scanned and regions of muscular pain will be digitally evaluated to develop a map of musculoskeletal pain regions. For this, a novel software will be used, provided by the Institute for Information Engineering, Wolfenbüttel.
Muscle strength will be assessed clinically by MRC grading (0-5), by quick motor function test (QMFT) and by dynamometry of selected muscles.
Pressure Pain Threshold (PPT) is defined as the minimum force applied which induces pain. Pressure algometry measurements will be performed to assess PPTs on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles. For muscle function and endurance, a six-minute walk test will be performed. If this test was performed within the last 3 months (e.g. for routine treatment/assessments), no new test will be performed and the last assessment will be documented (distance walked in meters, borg scale, vital parameters and date of assessment). In muscle ultrasound, alterations of muscle tissue will be evaluated in selected muscles of proximal muscles of upper and lower limbs, cervical, thoracic and lumbar vertebral muscles and rectus abdominis muscle. In laboratory assessments, polymorphisms of ACE and ACTN3 will be analyzed by molecular analysis. Levels of creatine kinase (CK) and Vitamin D, calcium, phosphate and magnesium will be analyzed. In a second step upon additional informed consent, blood samples will be analyzed by exome sequencing for mutations and variants in common genes associated with chronic pain syndromes.
- Being tested
- Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire), Fatigue Severity and Disability Scale (FSS) (Questionnaire), Rotterdam Handicap Scale (RHS) (Questionnaire)
- Medical subject headings
- Glycogen Storage Disease Type II, Myositis, Inclusion Body, Spinal Muscular Atrophies of Childhood
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beck depression inventory fast screen (Questionnaire)Diagnostic test
Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
Brief Pain Inventory (BPI) (Questionnaire)Diagnostic test
Validated questionnaire for pain.
German Pain Inventory (Questionnaire)Diagnostic test
Also called Deutscher Schmerzfragebogen (DSF)
German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
Fatigue Severity and Disability Scale (FSS) (Questionnaire)Diagnostic test
Validated questionnaire for perceived fatigue
Rotterdam Handicap Scale (RHS) (Questionnaire)Diagnostic test
validated questionnaire to assess a patient's functional ability and level of handicap
R-PAct (Questionnaire)Diagnostic test
The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
Quick Motor Function TestDiagnostic test
An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
Handheld Dynamometry (HHD)Diagnostic test
To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
Six-minute walk test (6MWT)Diagnostic test
It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
Pressure pain thresholdDiagnostic test
For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of "burning", "stinging", "drilling" or "aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
Muscle ultrasoundDiagnostic test
Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
Vital signsDiagnostic test
Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
Borg ScaleDiagnostic test
The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
Laboratory assessment: Creatine kinaseDiagnostic test
CK-Level assessment in peripheral blood (peripheral venous blood draw)
Laboratory assessment: Vitamin D LevelDiagnostic test
Vitamin D Level in peripheral blood (peripheral venous blood draw)
Laboratory assessment: calciumDiagnostic test
calcium level in peripheral blood (peripheral venous blood draw)
Laboratory assessment: magnesiumDiagnostic test
magnesium level in peripheral blood (peripheral venous blood draw)
Laboratory assessment: phosphateDiagnostic test
phosphate level in peripheral blood (peripheral venous blood draw)
Genetic test: ACE polymorphismGenetic
peripheral venous blood draw for genetic analysis of ACE polymorphism
Genetic test: ACTN3 polymorphismGenetic
peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
Blood draw for optional genetic exome sequencingGenetic
Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms "myalgia", "muscle pain", "chronic pain", "musculoskeletal pain", "pain", and "nociceptive pain".
| Study group | Role | What they receive |
|---|---|---|
| LOPD group | 50 Patients with genetically confirmed late-onset Pompe disease. Receives: Diagnostic Test: Beck depression inventory fast screen (Questionnaire); Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire); Diagnostic Test: German Pain Inventory (Questionnaire); Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire); Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire); Diagnostic Test: R-PAct (Questionnaire); Diagnostic Test: Quick Motor Function Test; Diagnostic Test: Handheld Dynamometry (HHD); Diagnostic Test: Six-minute walk test (6MWT); Diagnostic Test: Pressure pain threshold; Diagnostic Test: Muscle ultrasound; Diagnostic Test: Vital signs; Diagnostic Test: Borg Scale; Diagnostic Test: Laboratory assessment: Creatine kinase; Diagnostic Test: Laboratory assessment: Vitamin D Level; Diagnostic Test: Laboratory assessment: calcium; Diagnostic Test: Laboratory assessment: magnesium; Diagnostic Test: Laboratory assessment: phosphate; Genetic: Genetic test: ACE polymorphism; Genetic: Genetic test: ACTN3 polymorphism; Genetic: Blood draw for optional genetic exome sequencing | |
| Control group | 15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group. Receives: Diagnostic Test: Beck depression inventory fast screen (Questionnaire); Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire); Diagnostic Test: German Pain Inventory (Questionnaire); Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire); Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire); Diagnostic Test: R-PAct (Questionnaire); Diagnostic Test: Quick Motor Function Test; Diagnostic Test: Handheld Dynamometry (HHD); Diagnostic Test: Six-minute walk test (6MWT); Diagnostic Test: Pressure pain threshold; Diagnostic Test: Muscle ultrasound; Diagnostic Test: Vital signs; Diagnostic Test: Borg Scale; Diagnostic Test: Laboratory assessment: Creatine kinase; Diagnostic Test: Laboratory assessment: Vitamin D Level; Diagnostic Test: Laboratory assessment: calcium; Diagnostic Test: Laboratory assessment: magnesium; Diagnostic Test: Laboratory assessment: phosphate; Genetic: Genetic test: ACE polymorphism; Genetic: Genetic test: ACTN3 polymorphism; Genetic: Blood draw for optional genetic exome sequencing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of musculoskeletal pain in LOPD patients
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD).
Measured: Only at baseline visit
Secondary outcomes (9)
Association between musculoskeletal pain and muscle function, assessed by Medical research council (MRC) grading (0-5)
Assessed by Medical research council (MRC) grading (0-5) of selected muscles: on both sides deltoid muscles, biceps brachii muscles, triceps brachii muscles, hip flexors, hip extensors, quadriceps femoris muscles, foot extensor and foot flexor muscles as well as axial muscles and neck flexors and extensors. A maximum score of 95 means no weakness, a minimum score of 0 means tetraplegia.
Measured: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by quick motor function test (QMFT)
Assessed by quick motor function test (QMFT). The QMFT is a clinical test. An evaluator assesses the performance of a patient and scores the items separately on a 5-point ordinal scale, ranging from 0 (not able) to 4 (normal performance). A total score is obtained by adding the scores of all items. The total score ranges between 0 and 64 points, a higher score means better performance.
Measured: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by Pressure Pain Threshold (PPT)
Assessed by Pressure Pain Threshold (PPT). Pressure algometry is defined as the minimum force applied which induces pain. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles. The assessor places the pressure algometer on a site to be inspected in 3 series of slowly increasing stimulus (contact area 1cm2) intensities (0.5 kg/s, corresponding to ca. 50 kPa/s). A higher score means a higher pressure pain threshold. There is no cutoff or total score.
Measured: Only at baseline visit
Association between musculoskeletal pain and alterations of muscles, assessed by muscle ultrasound
To assess whether musculoskeletal pain regions are associated with muscle tissue alteration, evaluated by muscle ultrasound, using the Heckmatt scale 1 (no alteration) to IV (dystrophic muscle). Lower scale means healthier muscle.
Measured: Only at baseline visit
Association between musculoskeletal pain and Insertion-(I)-/Deletion-(D)-Polymorphisms of the ACE (angiotensin-converting enzyme; (ACE-I/D)) gene
ACE genotyping (angiotensin-converting enzyme I/D polymorphisms) to assess whether Insertion-(I)-/Deletion-(D)-Polymorphisms of the ACE gene are associated with musculoskeletal pain.
Measured: Only at baseline visit
Association between musculoskeletal pain and R-/X-polymorphisms of the Alpha-Actinin-3 (ACTN3) gene
ACTN3 genotyping (Alpha-Actinin-3 R-/X-polymorphisms) to assess whether R-/X-Polymorphisms of the ACTN3 gene are associated with musculoskeletal pain.
Measured: Only at baseline visit
Association between musculoskeletal pain and variants in defined genes, using exome sequencing
to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to nociceptive pain, using exome sequencing of selected genes.
Measured: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the German Pain Questionnaire
Characterization of quality and severity of musculoskeletal pain. The German Pain Questionnaire is a multidimensional questionnaire, based on several modules to characterize the quality of pain and consists of: demographic data, pain variables (e. g. pain sites, temporal characteristics, duration), pain associated symptoms, affective and sensory qualities of pain, pain-relieving and intensifying factors, previous pain treatment procedures, pain-related disability, comorbid conditions, social factors, and health-related quality of life. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used. However, there is no total score that indicates e.g. lower or higher pain.
Measured: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the Brief Pain Inventory (BPI)
To assess the severity of pain and the impact of pain on daily functions. The two categories Pain Intensity and Pain Interference are rated by patients on a scale from 0-10, 10 being excruciating pain intensity and a complete interference in their life. There is no scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference.
Measured: Only at baseline visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2022
- Study start31 Mar 2022
- Primary completion30 May 2024 (estimated)
- Study completion3 Sep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pompe Disease (Late-onset)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 95 participants (estimated)
Sponsor and investigators
- Lead sponsor
- LMU Klinikum
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. Benedikt Schoser, LMU Klinikum
- Investigators
- Stephan Wenninger, PD Dr. med., Principal investigator, Study Principal Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05272969
- Sponsor's protocol ID
- Pompe&Pain
- Status last verified
- Oct 2023
- First submitted
- 28 Jan 2022
- Last updated
- 10 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD)
- ClinicalTrials.gov ID
- NCT05272969
- Acronym / sponsor ID
- Pompe&Pain
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 95 participants (estimated)
- Lead sponsor
- LMU KlinikumUniversity, hospital or other
- Study start
- 31 Mar 2022 (actual)
- Primary completion
- 30 May 2024 (estimated)
- Study completion
- 3 Sep 2024 (estimated)
- First posted
- 10 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). The secondary objectives are to evaluate whether muscle pain is associated with muscle function, to assess whether muscle pain is associated with alterations of muscle tissue, and whether vitamin D metabolism and polymorphisms of ACE and ACTN3 genes may contribute to an increased level of perceived musculoskeletal pain. In a second step, exome sequencing of genes associated with musculoskeletal pain will be analyzed. Results of LOPD patients will be compared to patients with neuromuscular disorders with a similar distribution of muscle weakness and/or musculoskeletal pain.
Detailed description
In this nationwide, explorative, cross-sectional study in Germany, approx. 50 patients with genetically confirmed late-onset Pompe disease (LOPD) will be included into the study. In addition, 15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group. The duration of patient recruitment will be around 18 months. The primary aim is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD). The secondary objectives are to evaluate whether muscle pain is associated with muscle function, measured by quantitative muscle testing and pressure pain threshold (PPT), to assess whether muscle pain is associated with alterations of muscle tissue, measured by muscle ultrasound and whether vitamin D metabolism and polymorphisms of ACE and ACTN3 genes may contribute to an increased level of perceived musculoskeletal pain. In a second step, exome sequencing of genes associated with musculoskeletal pain will be analyzed. Results of LOPD patients will be compared to patients with neuromuscular disorders with a similar distribution of muscle weakness and/or musculoskeletal pain.
After screening of 120 patients, approximately 50 patients with late-onset Pompe disease, 15 patients with IBM, 15 patients with FSHD and 15 patients with SMA3, who meet all eligibility criteria, will be enrolled in the study. All patients will be required to attend once at a study site to perform all study-related procedures. The study procedures will take approx. 3 hours.
Demographic and disease-related data (age, gender, weight, height, diagnosis, a historical genetic test results and/or muscle biopsy results, age at onset of symptoms, age at diagnosis, severity and distribution of muscle weakness, prior and concomitant medication, medical history, ventilation status) will be obtained. Patients will fill out validated disease-related and quality-of-life questionnaires: Brief Pain Inventory, Rotterdam Handicap Scale, Fatigue Severity Scale, R-PAct, and German Pain Questionnaire. Patients will be asked to sketch regions of perceived musculoskeletal pain on a body figure, which is provided on a tablet or a paper version. The paper version will be scanned and regions of muscular pain will be digitally evaluated to develop a map of musculoskeletal pain regions. For this, a novel software will be used, provided by the Institute for Information Engineering, Wolfenbüttel.
Muscle strength will be assessed clinically by MRC grading (0-5), by quick motor function test (QMFT) and by dynamometry of selected muscles.
Pressure Pain Threshold (PPT) is defined as the minimum force applied which induces pain. Pressure algometry measurements will be performed to assess PPTs on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles. For muscle function and endurance, a six-minute walk test will be performed. If this test was performed within the last 3 months (e.g. for routine treatment/assessments), no new test will be performed and the last assessment will be documented (distance walked in meters, borg scale, vital parameters and date of assessment). In muscle ultrasound, alterations of muscle tissue will be evaluated in selected muscles of proximal muscles of upper and lower limbs, cervical, thoracic and lumbar vertebral muscles and rectus abdominis muscle. In laboratory assessments, polymorphisms of ACE and ACTN3 will be analyzed by molecular analysis. Levels of creatine kinase (CK) and Vitamin D, calcium, phosphate and magnesium will be analyzed. In a second step upon additional informed consent, blood samples will be analyzed by exome sequencing for mutations and variants in common genes associated with chronic pain syndromes.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LOPD group | – | Diagnostic Test: Beck depression inventory fast screen (Questionnaire), Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire), Diagnostic Test: German Pain Inventory (Questionnaire), Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire), Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire), Diagnostic Test: R-PAct (Questionnaire), Diagnostic Test: Quick Motor Function Test, Diagnostic Test: Handheld Dynamometry (HHD), Diagnostic Test: Six-minute walk test (6MWT), Diagnostic Test: Pressure pain threshold, Diagnostic Test: Muscle ultrasound, Diagnostic Test: Vital signs, Diagnostic Test: Borg Scale, Diagnostic Test: Laboratory assessment: Creatine kinase, Diagnostic Test: Laboratory assessment: Vitamin D Level, Diagnostic Test: Laboratory assessment: calcium, Diagnostic Test: Laboratory assessment: magnesium, Diagnostic Test: Laboratory assessment: phosphate, Genetic: Genetic test: ACE polymorphism, Genetic: Genetic test: ACTN3 polymorphism, Genetic: Blood draw for optional genetic exome sequencing50 Patients with genetically confirmed late-onset Pompe disease. |
| Control group | – | Diagnostic Test: Beck depression inventory fast screen (Questionnaire), Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire), Diagnostic Test: German Pain Inventory (Questionnaire), Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire), Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire), Diagnostic Test: R-PAct (Questionnaire), Diagnostic Test: Quick Motor Function Test, Diagnostic Test: Handheld Dynamometry (HHD), Diagnostic Test: Six-minute walk test (6MWT), Diagnostic Test: Pressure pain threshold, Diagnostic Test: Muscle ultrasound, Diagnostic Test: Vital signs, Diagnostic Test: Borg Scale, Diagnostic Test: Laboratory assessment: Creatine kinase, Diagnostic Test: Laboratory assessment: Vitamin D Level, Diagnostic Test: Laboratory assessment: calcium, Diagnostic Test: Laboratory assessment: magnesium, Diagnostic Test: Laboratory assessment: phosphate, Genetic: Genetic test: ACE polymorphism, Genetic: Genetic test: ACTN3 polymorphism, Genetic: Blood draw for optional genetic exome sequencing15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- After screening of 120 patients, approximately 50 patients with late-onset Pompe disease, 15 patients with IBM, 15 patients with FSHD and 15 patients with SMA3, who meet all eligibility criteria, will be enrolled in the study. All patients must be ≥ 18 years of age.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beck depression inventory fast screen (Questionnaire)Beck depression inventory fast screen questionnaire to detect severe depression for eligibility. | Diagnostic test | Control group, LOPD group |
| Brief Pain Inventory (BPI) (Questionnaire)Validated questionnaire for pain. | Diagnostic test | Control group, LOPD group |
| German Pain Inventory (Questionnaire)Also: Deutscher Schmerzfragebogen (DSF)German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used. | Diagnostic test | Control group, LOPD group |
| Fatigue Severity and Disability Scale (FSS) (Questionnaire)Validated questionnaire for perceived fatigue | Diagnostic test | Control group, LOPD group |
| Rotterdam Handicap Scale (RHS) (Questionnaire)validated questionnaire to assess a patient's functional ability and level of handicap | Diagnostic test | Control group, LOPD group |
| R-PAct (Questionnaire)The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options. | Diagnostic test | Control group, LOPD group |
| Quick Motor Function TestAn evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points. | Diagnostic test | Control group, LOPD group |
| Handheld Dynamometry (HHD)To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion. | Diagnostic test | Control group, LOPD group |
| Six-minute walk test (6MWT)It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once. | Diagnostic test | Control group, LOPD group |
| Pressure pain thresholdFor diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of "burning", "stinging", "drilling" or "aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles. | Diagnostic test | Control group, LOPD group |
| Muscle ultrasoundMuscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes. | Diagnostic test | Control group, LOPD group |
| Vital signsVital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT). | Diagnostic test | Control group, LOPD group |
| Borg ScaleThe Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes). | Diagnostic test | Control group, LOPD group |
| Laboratory assessment: Creatine kinaseCK-Level assessment in peripheral blood (peripheral venous blood draw) | Diagnostic test | Control group, LOPD group |
| Laboratory assessment: Vitamin D LevelVitamin D Level in peripheral blood (peripheral venous blood draw) | Diagnostic test | Control group, LOPD group |
| Laboratory assessment: calciumcalcium level in peripheral blood (peripheral venous blood draw) | Diagnostic test | Control group, LOPD group |
| Laboratory assessment: magnesiummagnesium level in peripheral blood (peripheral venous blood draw) | Diagnostic test | Control group, LOPD group |
| Laboratory assessment: phosphatephosphate level in peripheral blood (peripheral venous blood draw) | Diagnostic test | Control group, LOPD group |
| Genetic test: ACE polymorphismperipheral venous blood draw for genetic analysis of ACE polymorphism | Genetic | Control group, LOPD group |
| Genetic test: ACTN3 polymorphismperipheral venous blood draw for genetic analysis of ACTN3 polymorphism | Genetic | Control group, LOPD group |
| Blood draw for optional genetic exome sequencingOptionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms "myalgia", "muscle pain", "chronic pain", "musculoskeletal pain", "pain", and "nociceptive pain". | Genetic | Control group, LOPD group |
Primary outcome
Prevalence of musculoskeletal pain in LOPD patients
Time frame: Only at baseline visit
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD).
9 secondary outcomes
Association between musculoskeletal pain and muscle function, assessed by Medical research council (MRC) grading (0-5)
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by quick motor function test (QMFT)
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by Pressure Pain Threshold (PPT)
Time frame: Only at baseline visit
Association between musculoskeletal pain and alterations of muscles, assessed by muscle ultrasound
Time frame: Only at baseline visit
Association between musculoskeletal pain and Insertion-(I)-/Deletion-(D)-Polymorphisms of the ACE (angiotensin-converting enzyme; (ACE-I/D)) gene
Time frame: Only at baseline visit
Association between musculoskeletal pain and R-/X-polymorphisms of the Alpha-Actinin-3 (ACTN3) gene
Time frame: Only at baseline visit
Association between musculoskeletal pain and variants in defined genes, using exome sequencing
Time frame: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the German Pain Questionnaire
Time frame: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the Brief Pain Inventory (BPI)
Time frame: Only at baseline visit
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2023.
- Individual participant dataSharing planned: No
Related trials for Pompe Disease (Late-onset)
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingObservational study
Pompe Disease Registry Protocol
Glycogen Storage Disease Type II, Pompe Disease
Not yet recruitingPhase 2
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
Pompe Disease
RecruitingPhase 1/2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
Pompe Disease (Late-onset), Pompe Disease Late-Onset
Active, not recruiting
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
Pompe Disease (Late-onset)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephan Wenninger, PD Dr. med. principal investigator
Study Principal Investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pompe Disease (Late-onset) and Inclusion Body Myositis, run by LMU Klinikum at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Stephan Wenninger, PD Dr. med. (4989440057470, stephan.wenninger@med.uni-muenchen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of musculoskeletal pain in LOPD patients (time frame: Only at baseline visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.